Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,330Revenue $M0.0Net Margin (%)--Altman Z-Score-8.8
Enterprise Value $M2,432EPS $-0.5Operating Margin %--Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)--Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-20.0Quick Ratio0.4Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-26.3Current Ratio0.4Lower Leverage y-yY
Price/Free Cash Flow106y-y EBITDA Growth Rate %--ROA % (ttm)-55.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M410ROIC % (ttm)-271.7Gross Margin Increase y-yN

Gurus Latest Trades with MNKD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
MNKDFirst Eagle Investment 2013-03-31 Sold Out -0.01%$2.31 - $3.56
$ 5.3293%Sold Out0
MNKDFirst Eagle Investment 2012-12-31 Buy 0.01%$1.85 - $2.83
$ 5.32146%New holding800,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MNKD is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

MNKD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Martens JuergenCorporate VP and COO 2015-05-21Buy20,000$4.5716.41 view
Edstrom HakanPresident & CEO 2015-04-24Sell73,460$4.8310.14 view
Edstrom HakanPresident & CEO 2015-03-27Sell73,460$5.212.11 view
Martens JuergenCorporate VP and COO 2015-03-02Sell121,333$6.54-18.65 view
Thomson DavidVP & General Counsel 2015-02-19Sell68,662$7.19-26.01 view
Edstrom HakanPresident & CEO 2015-02-10Sell73,460$7.75-31.35 view
Palumbo DianeVice President, Human Resource 2015-02-05Sell149,833$6.95-23.45 view
Thomson DavidVP & General Counsel 2015-02-05Sell80,000$7-24 view
Edstrom HakanPresident & CEO 2015-01-30Sell73,460$6.34-16.09 view
Palumbo DianeVice President, Human Resource 2015-01-05Sell188,999$5.95-10.59 view

Quarterly/Annual Reports about MNKD:

News about MNKD:

Articles On GuruFocus.com
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
own Mar 02 2015 
investment Feb 28 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
Portfolio 1 Jan 03 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 

More From Other Websites
Analysts Battle Over MannKind -- but Who's Right? Jul 01 2015
MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin Jun 30 2015
Edited Transcript of MNKD presentation 24-Jun-15 1:30pm GMT Jun 29 2015
The 6 Most Heavily Shorted Nasdaq Stocks in June Jun 25 2015
Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail! Jun 19 2015
MannKind's 3 Can't-Miss Quotes at Goldman Sachs Jun 17 2015
MannKind Corporation Sinks: CFO Says 'We're Not There Yet' With Afrezza Jun 10 2015
5 Stocks a Raging Rally Could Not Save Jun 10 2015
The 6 Most Shorted Nasdaq Stocks in May Jun 10 2015
Why MannKind Could Be an Endless Tug-of-War Stock Jun 09 2015
Diabetes Docs Wary of MannKind's Afrezza Insulin, Analyst Survey Finds Jun 09 2015
Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala Jun 09 2015
Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala Jun 09 2015
3 Big Stocks on Traders' Radars -- and What to Do With Them Jun 08 2015
MannKind (MNKD) Worth a Look: Stock Adds 5.7% in Session - Tale of the Tape Jun 08 2015
Jefferies: MannKind's Consumer Ads For Afrezza May Increase Awareness Jun 04 2015
MannKind Continues To Be Friendly To Investors Jun 03 2015
MannKind's inhaled insulin drug proves hard for diabetics to get Jun 03 2015
Is This Diabetes Stock a Better Bet Than MannKind? May 27 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)